Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kelun Biotech Plans Hong Kong IPO to Develop ADCs and Other Products

publication date: Feb 27, 2023

Chengdu Kelun Biotech, a subsidiary of Sichuan Kelun Pharma, will stage an IPO on the Hong Kong Exchange. Kelun develops novel biologics – especially ADCs -- and small molecule drugs for oncology, autoimmune, inflammatory and metabolic indications. In 2022, Kelun out-licensed ex-China rights for some of its products to Merck/MSD in three separate agreements with a value of up to $12 billion, a record amount. Using its proprietary platforms, Kelun Bio has built a portfolio of 33 novel candidates, including 13 assets in clinical trials. It has filed a China NDA for its anti-PD-L1 candidate as a nasopharyngeal cancer therapy. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital